DISEASE INDICATIONS: Lung Cancer
MANUFACTURER: AstraZeneca AB
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Tagrisso has been a game-changer, specifically targeting EGFR (epidermal growth factor receptor) mutations, which are prevalent in a subset of NSCLC patients.
